The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 14 April 2026•Updated 16 April 2026•

1 min read

Kuros Biosciences Q1 2026 Sales Surge 51% Driven by MagnetOs Growth

Key Facts

1Total product sales increased by 51% to USD 43.4 million in Q1 2026.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: The story was updated to include Q1 2026 financial results from Mauna Kea Technologies, which showed similar growth trends to Kuros Biosciences within the medical technology sector.

Kuros Biosciences reported a robust financial performance for the first quarter of 2026, highlighted by a 51% year-over-year surge in total product sales to USD 43.4 million driven by its MagnetOs line. Joining the sector's positive trend, Mauna Kea Technologies also reported strong core sales growth for Q1 2026, fueled by momentum in the U.S. market and international expansion. Mauna Kea's CEO confirmed that this performance reinforces the growth trajectory initiated in 2025 for the company's Cellvizio platform. Meanwhile, Kuros' EBITDA rose to USD 2.9 million, up from USD 2.0 million in Q1 2025, reflecting significant operational momentum despite a decrease in cash reserves due to strategic production investments. These combined results underscore a strengthening position for medical technology firms in the global market.